ASP2151 for the Treatment of Genital Herpes: A Randomized, Double-Blind, Placebo- and Valacyclovir-Controlled, Dose-Finding Study-Reference-Cited by-同舟云学术

ASP2151 for the Treatment of Genital Herpes: A Randomized, Double-Blind, Placebo- and Valacyclovir-Controlled, Dose-Finding Study

Published:2012-02-20 Issue:7 Volume:205 Page:1100-1110
ISSN:1537-6613
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Tyring Stephen,Wald Anna,Zadeikis Neddie,Dhadda Shobha,Takenouchi Kazumasa,Rorig Ramona

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/205/7/1100/18066848/jis019.pdf

Reference18 articles.

1. Herpes simplex virus resistance to antiviral drugs;Morfin;J Clin Virol,2003

2. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics;Reyes;Arch Intern Med,2003

3. Once-daily valacyclovir to reduce the risk of transmission of genital herpes;Corey;N Engl J Med,2004

4. ASP2151, a novel hesicase-primase inhibitor, is an antivirus candidate for infections of varicella-zoster virus and herpes simplex virus types 1 and 2;Chono;J Antimicrob Chemother,2010

5. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group;Bodsworth;Genitourin Med,1997

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment and prevention of herpes simplex virus type 1 in immunocompetent adolescents and adults;South African General Practitioner;2024-03

2. Herpes Simplex Virus and Varicella Zoster Virus Infections in Cancer Patients;Viruses;2023-02-05

3. Management of neonatal central nervous system viral infections: Knowledge gaps and research priorities;Reviews in Medical Virology;2023-01-13

4. Acyclovir resistance in herpes simplex viruses: Prevalence and therapeutic alternatives;Biochemical Pharmacology;2022-12

5. A phase 3, randomized, double‐blind, placebo‐controlled study evaluating a single, patient‐initiated dose of amenamevir for recurrent herpes labialis;The Journal of Dermatology;2022-11-09